Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity

被引:60
作者
Aletaha, Daniel [1 ]
Alasti, Farideh [1 ]
Smolen, Josef S. [1 ,2 ]
机构
[1] Med Univ Vienna, Div Rheumatol, Dept Med 3, A-1090 Vienna, Austria
[2] Hietzing Hosp, Dept Med 2, Vienna, Austria
关键词
CITRULLINATED PEPTIDE ANTIBODY; IMMUNE-COMPLEXES; RHEUMATOLOGY/EUROPEAN LEAGUE; RADIOGRAPHIC PROGRESSION; CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; JOINT DAMAGE; TNF-ALPHA; METHOTREXATE; COMPLEMENT;
D O I
10.1136/annrheumdis-2012-201517
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background Rheumatoid factor (RF) is prototypic for rheumatoid arthritis (RA) and serves diagnostic and prognostic purposes. RF is associated with joint destruction, but the role of disease activity as a potential mediator of these effects has not been clearly elucidated yet. Objective To investigate if higher radiographic progression (Sharp score, Delta TSS) in RF+ patients is dependent or independent of disease activity. Methods The authors performed a cross-sectional multivariate analysis at baseline and a matched cohort study in patients from five RA clinical trials. The authors pooled methotrexate treatment arms and compared Delta TSS in RF+ and RF-patients before and after matching for other associated variables. Results Among 686 patients, 124 were RF- and 562 RF +, 343 having high (>160 U/ml) RF. Delta TSS was 1.03 +/- 5.83, 3.23 +/- 8.10 and 3.58 +/- 8.18 (p<0.0001), respectively, and similarly for erosions and joint space narrowing (JSN). After matching for other prognostically important variables, Delta TSS still was lower among 61 RF-versus 61 RF high+ patients (0.52 +/- 2.47 vs 3.09 +/- 8.28; p=0.028), mainly related to differences in erosion score (0.31 +/- 1.88 vs 2.07 +/- 5.62; p=0.035), but not JSN (0.21 +/- 1.26 vs 1.02 +/- 3.31; p=0.162). Conclusions The data reveal that damage progression in seropositive RA patients is related to higher levels of disease activity and to independent effects of RF, particularly on bone damage. This calls for consideration of RF status irrespective of disease activity.
引用
收藏
页码:875 / 880
页数:6
相关论文
共 51 条
[1]
ALARCON GS, 1990, ARTHRITIS RHEUM-US, V33, P1156
[2]
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[3]
Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment [J].
Aletaha, D. ;
Funovits, J. ;
Breedveld, F. C. ;
Sharp, J. ;
Segurado, O. ;
Smolen, J. S. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (05) :1242-1249
[4]
Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
[5]
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].
Aletaha, Daniel ;
Neogi, Tuhina ;
Silman, Alan J. ;
Funovits, Julia ;
Felson, David T. ;
Bingham, Clifton O., III ;
Birnbaum, Neal S. ;
Burmester, Gerd R. ;
Bykerk, Vivian P. ;
Cohen, Marc D. ;
Combe, Bernard ;
Costenbader, Karen H. ;
Dougados, Maxime ;
Emery, Paul ;
Ferraccioli, Gianfranco ;
Hazes, Johanna M. W. ;
Hobbs, Kathryn ;
Huizinga, Tom W. J. ;
Kavanaugh, Arthur ;
Kay, Jonathan ;
Kvien, Tore K. ;
Laing, Timothy ;
Mease, Philip ;
Menard, Henri A. ;
Moreland, Larry W. ;
Naden, Raymond L. ;
Pincus, Theodore ;
Smolen, Josef S. ;
Stanislawska-Biernat, Ewa ;
Symmons, Deborah ;
Tak, Paul P. ;
Upchurch, Katherine S. ;
Vencovsky, Jiri ;
Wolfe, Frederick ;
Hawker, Gillian .
ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581
[6]
Therapeutic blockade of TNF in patients with SLE-Promising or crazy? [J].
Aringer, Martin ;
Smolen, Josef S. .
AUTOIMMUNITY REVIEWS, 2012, 11 (05) :321-325
[7]
THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[8]
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[9]
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[10]
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443